Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Harmony Biosciences Holdings ( (HRMY) ) has provided an update.
Harmony Biosciences Holdings, Inc. held its 2026 Annual Meeting of Stockholders on May 14, 2026, with 50,381,309 shares represented, constituting a quorum for the proceedings. Stockholders voted on director elections, ratification of the independent auditor, and an advisory resolution on executive compensation, shaping the company’s corporate governance for the coming years.
Shareholders elected four Class III directors, Geno Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki, Ph.D., to serve until the 2029 Annual Meeting and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Investors also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, signaling continued shareholder support for existing leadership and governance practices.
The most recent analyst rating on (HRMY) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Harmony Biosciences Holdings stock, see the HRMY Stock Forecast page.
Spark’s Take on HRMY Stock
According to Spark, TipRanks’ AI Analyst, HRMY is a Outperform.
The score is driven primarily by strong financial quality (high margins, robust cash conversion, and a very strong/low-leverage balance sheet). Earnings-call fundamentals add support via reiterated blockbuster revenue guidance and multiple pipeline catalysts, while the stock’s technical picture is only moderately positive due to being below longer-term moving averages. Valuation is supportive with a ~12.5 P/E, and recent leadership changes are a modest positive with some transition risk.
To see Spark’s full report on HRMY stock, click here.
More about Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases and disorders. The company targets underserved markets where there are significant unmet medical needs, aiming to expand treatment options and improve quality of life for affected patient populations.
Average Trading Volume: 1,009,503
Technical Sentiment Signal: Sell
Current Market Cap: $1.75B
For an in-depth examination of HRMY stock, go to TipRanks’ Overview page.